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Key points 
• Btk blockade by ibrutinib and acalabrutinib delays but does not block platelet 
aggregation to maximal GPVI stimulation 
• Clinical doses of Ibrutinib but not acalabrutinib block platelet aggregation to 
GPVI agonists due to off-target effects  
 
Abstract 
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton’s tyrosine kinase used 
in the treatment of B cell malignancies. They bind irreversibly to cysteine 481 of 
Bruton’s tyrosine kinase, blocking autophosphorylation on tyrosine 223 and 
phosphorylation of downstream substrates including phospholipase- 2. In the 
present study, we demonstrate that concentrations of ibrutinib and acalabrutinib that 
block Bruton’s tyrosine kinase activity as shown by loss of phosphorylation at 
tyrosine 223 and phospholipase- 2 delay but do not block aggregation to a 
maximally-effective concentration of collagen related peptide or collagen. In contrast, 
10-20 fold higher concentrations of ibrutinib or acalabrutinib block platelet 
aggregation to Glycoprotein VI agonists. Ex vivo studies on patients treated with 
ibrutinib, but not acalabrutinib, show a reduction of platelet aggregation to collagen 
related peptide indicating that the clinical dose of ibrutinib but not acalabrutinib is 
supramaximal for Bruton’s tyrosine kinase blockade. Unexpectedly, low 
concentrations of ibrutinib inhibit aggregation to collagen related peptide in patients 
deficient in Bruton’s tyrosine kinase. The increased bleeding seen with ibrutinib over 
acalabrutinib is due to off-target actions of ibrutinib that occur because of 
unfavourable pharmacodynamics.  
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Introduction 
The major physiological ligands that activate platelets in haemostasis and 
thrombosis signal through G protein-coupled and tyrosine kinase-linked receptors. 
The former includes receptors for thrombin (PAR1, PAR4), thromboxane A2 (TP) and 
ADP (P2Y1, P2Y12), and the latter receptors for collagen/fibrin (GPVI), podoplanin 
(CLEC-2), von Willebrand Factor (GPIb-IX-V) and fibrinogen (integrin αIIbβ3)1,2.  
GPVI is a receptor for collagen and fibrin which forms a complex with the Fc receptor 
 -chain (FcR )2-4. GPVI triggers powerful platelet activation through Src, Syk and 
Tec family tyrosine kinases leading to activation of PLC 25. GPVI is expressed 
exclusively on platelets and the platelet precursor cell the megakaryocyte6. Mice 
deficient in GPVI have a minor increase in tail bleeding times but fail to form 
occlusive thrombi in a FeCl3 injury arterial thrombosis assay7. Patients homozygous 
for an insertion that introduces a stop codon and prevents expression of the 
immunoglobulin receptor on the platelet surface have a relatively mild bleeding 
diathesis8, although they are too few in number to know if they are protected from 
thrombosis.  
Bruton’s tyrosine kinase (Btk) is a member of the Tec family of tyrosine kinases and 
mediates phosphorylation and activation of PLC 2 downstream of GPVI and the B 
cell antigen receptor. The irreversible Btk inhibitor ibrutinib has been introduced in 
the clinic for treatment of B cell malignancies but has been reported to increase rates 
of major haemorrhage in a sub-group of patients9,10. The increase in bleeding has 
been attributed to loss of platelet activation by GPVI11-13 and GPIb11, with the 
inhibition of the two receptors having been shown to correlate14. 
In contrast to treatment with ibrutinib, patients with X-linked Agammaglobulinemia 
(XLA) do not bleed excessively15. XLA is caused by mutations in the Btk gene that 
result in loss or reduction in Btk expression, or expression of a non-functional 
protein. A potential explanation for this discrepancy is that ibrutinib blocks activation 
of platelets by both Btk and the closely related kinase Tec. Tec is expressed in 
human and mouse platelets, and has been shown to support PLC 2 activation in 
mouse platelets16. Interestingly, major haemorrhage is not seen with the structurally 
related Btk inhibitor, acalabrutinib, despite also inhibiting Btk by covalent modification 
of C4819,17. It has been postulated that this is due to its greater selectivity to Btk over 
Tec in comparison to ibrutinib17,18. 
In the present study we have compared the inhibitory effects of ibrutinib and 
acalabrutinib on platelet activation and protein phosphorylation by GPVI alongside ex 
vivo studies on patients prescribed the two inhibitors, as well as on XLA patients. 
 
Methods 
Reagents 
Details on the source of reagents and chemical analyses can be found in the 
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supplemental information.  
 
Light transmission aggregometry (LTA) 
Aggregation was measured in siliconised glass vials at 37°C in a Model 700 
aggregometer (ChronoLog, Havertown, PA) with stirring at 1200 rpm. Platelets were 
warmed to 37°C for 5 min before experimentation. Platelets were pre-incubated with 
ibrutinib, acalabrutinib or DMSO vehicle for 5 min prior to agonist addition unless 
otherwise stated. Results were averaged and IC50 values were calculated from these 
data. 
 
Protein phosphorylation 
Washed platelets were pre-treated with 9 μM eptifibatide to block integrin αIIbβ3 
activation. Agonists were added while stirring at 1200 rpm in an aggregometer at 
37°C for 180 sec unless stated otherwise. Stimulations were performed in the 
presence of ibrutinib (17 nM - 7 μM), acalabrutinib (50 nM – 200 μM) or vehicle 
(DMSO). For whole cell lysate experiments; activation was terminated with 5X SDS 
reducing sample buffer. For immunoprecipitation; 8x108/mL platelets were used and 
reactions were terminated by addition of 2X ice-cold Nonidet P-40 lysis buffer 
containing the protease inhibitors sodium orthovanadate (5 mM), leupeptin (10 
μg/mL), AEBSF (200 μg/mL), aprotinin (10 μg/mL) and pepstatin (1 μg/mL). Platelet 
lysates were precleared, and detergent-insoluble debris was discarded. An aliquot 
was dissolved with SDS sample buffer for detection of total tyrosine phosphorylation. 
Lysates were incubated with either the indicated antibodies and protein A- or protein 
G-Sepharose. Lysates were separated by SDS-PAGE, electro-transferred, and 
Western blotted. Western blots were imaged using ECL autoradiography film. For 
analysis of levels of phosphorylation, Western blot films were scanned and band 
intensity measured using ImageJ 1.5 with values normalised to basal levels. Results 
were averaged and IC50 values were calculated from these data. 
 
Other 
Details on methods for blood sampling, platelet preparation, granule release, [Ca2+]i 
mobilisation, measurement of platelet adhesion under flow, cell lines, plasmids, 
transfections and the luciferase assay can be found in the supplemental information. 
 
Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM) with statistical 
significance taken as p < 0.05 unless otherwise stated. Statistical analyses, unless 
otherwise specified, were performed using one-way ANOVA with a Bonferroni post-
test. Ex vivo platelet aggregation optical densities were compared using a one-way 
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ANOVA with Tukey’s multiple comparison test. Correlation of aggregation and 
tyrosine phosphorylation was assessed using Pearson’s correlation coefficient. 
Statistical analysis of the IC50 values was performed using Welch’s t-test. All 
statistical analyses were performed using GraphPad Prism 7. 
 
Ethical Approval 
 
Ethical approval for collecting blood from patients and healthy volunteers was 
granted by the National Research Ethics Service (10/H1206/58) and Birmingham 
University Internal Ethical Review (ERN_11-0175) respectively. Work on HLA 
patients has ethical approval via the University of Birmingham HBRC 16-251 
Amendment 1. 
 
Results 
Inhibition of GPVI-induced platelet aggregation by high concentrations of 
ibrutinib is reversible  
Ibrutinib is 97% plasma protein bound and unbound levels reach approximately 0.5 
μM in patients11. At this concentration, ibrutinib has been shown to block GPVI-
induced platelet aggregation12,19. If this is due to inhibition of Btk and other Tec 
kinases then the inhibition should be irreversible and time-dependent (i.e. inhibition 
should increase with time). To test this, platelets were treated with a concentration of 
ibrutinib that causes complete inhibition of GPVI-mediated aggregation in washed 
platelets before washout of ibrutinib and stimulation with the GPVI-specific agonist 
collagen-related-peptide (CRP). Platelets showed almost full recovery on washout 
demonstrating that the inhibitory effect is not due solely to covalent modification of 
Btk or Tec (Figure 1A and 1B). In support of this, incubation for ≥30 sec in washed 
platelets with a high concentration of ibrutinib (700 nM) was sufficient to block 
aggregation to a high dose of CRP (Figure 1C). However, at a lower concentration, 
ibrutinib (70 nM) caused a time-dependent delay in aggregation to a high 
concentration of CRP that was apparent at incubation times of ≥ 5 min (Figure 1D 
and 2Ai). This concentration of ibrutinib also caused a reduced response to a sub-
maximal concentration of CRP (Supplementary Figure 2A). The time-dependent 
delay is consistent with an irreversible action and contrasts with the rapid onset of 
inhibition observed at the high concentration of ibrutinib. A similar set of observations 
were seen in washed platelets stimulated by collagen (Supplementary Figure 1A). 
Similar results were also seen in the presence of 0.3% BSA which was used in case 
the results were influenced by adsorption of ibrutinib to the surface of the 
aggregometer tube (Supplementary Figure 1B). 
Platelet secretion and Ca2+ mobilisation play key roles in platelet activation. 
Consistent with the results for aggregation, low (70 nM) and high (700 nM) 
concentrations of ibrutinib have no effect or block ATP secretion to a high 
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concentration of CRP, respectively (Figure 2Bi and 2Biii). Similarly, the peak Ca2+ 
concentration to a high concentration of CRP was not altered in the presence of a 
low concentration of ibrutinib (70 nM) but was markedly reduced by a high 
concentration (700 nM). The dose response curve for inhibition of aggregation was 
similar to that for loss of Ca2+ mobilisation (Figure 2Bii and 2Biii) and was not 
affected by the presence of the cyclooxygenase inhibitor indomethacin 
(Supplementary Figure 1D). There was no statistical difference between the IC50 of 
ibrutinib for secretion, aggregation or Ca2+ mobilisation. 
Taken together these results show that ibrutinib has two distinct effects on platelet 
activation by CRP. At a low concentration (70 nM), ibrutinib delays but does not 
inhibit activation, whereas at a tenfold higher concentration of ibrutinib (700 nM) 
activation is blocked. The latter action is reversible indicating that it is not mediated 
by covalent modification of Btk or other Tec kinases.  
Low dose ibrutinib blocks Btk but not Tec  
The concentration response curve to ibrutinib on tyrosine phosphorylation was 
investigated in washed platelets in the same conditions as for the platelet function 
studies above. CRP induced robust tyrosine phosphorylation in whole cell lysates 
which was dose-dependently inhibited by ibrutinib. Correspondingly with the results 
for aggregation, this inhibitory effect of ibrutinib on global tyrosine phosphorylation 
was also reversible on washout (Figure 3Ai). Using phosphospecific antibodies, we 
were able to see that the inhibition of Src Y418 (which lies upstream of Btk) was also 
reversible but that autophosphorylation of Btk at Y223 and Btk substrates PLC 2 
Y753 and Y121711, 20 were irreversible (Figure 3Ai-ii). 
A detailed analysis of the dose response to ibrutinib on a wider range of proteins in 
the GPVI signalling cascade was investigated using further phosphospecific 
antibodies (Figure 3Bi). Autophosphorylation of Btk and downstream PLC 2 was 
reduced to basal levels by a low dose of ibrutinib (70 nM) (Figure 3Bii). In contrast, 
phosphorylation of Btk on Y551, which is mediated by Src family kinases21, and 
proteins that lie upstream of Btk, namely Src Y418, Syk Y525/6, SLP-76 Y145 and 
LAT Y200, was not altered (Figure 3Biii-iv). Inhibition of phosphorylation of Src on its 
activation site, Y418, was observed at a tenfold higher concentration of ibrutinib 
(Figure 3Biv) and shown to correlate with inhibition of aggregation (Pearson’s 
correlation coefficient 0.959). Inhibition of whole cell phosphorylation and 
phosphorylation of Syk Y525/6, SLP-76 Y145, Btk Y551 and LAT Y200 was seen at 
7 μM ibrutinib which is tenfold higher than the maximal concentration in patients 
(Figure 3Bii and 3Biii). Where calculatable, the IC50 values for each phosphorylation 
event are included in Supplementary Table 1. Blockade of Btk pY223 and PLC 2 
phosphorylation by 70 nM ibrutinib was also observed with lower concentrations of 
CRP or in the absence of the integrin αIIbβ3 blocker, eptifibatide (Supplementary 
Figure 2Aiv and 2B). There was no significant increase in phosphorylation of PLC 2 
up to 180 sec in response to CRP in the presence of 70 nM ibrutinib (Supplementary 
Figure 2Ci-iii).  
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Due to the absence of phosphospecific antibodies for the Btk related Tec family 
kinase, Tec, the effect of ibrutinib on Tec phosphorylation was investigated following 
immunoprecipitation and re-probing with the antiphosphotyrosine mAb 4G10. The 
effect of ibrutinib was biphasic with partial blockade at 170 nM and full blockade 
observed at 7 μM (Figure 3C).  
These results demonstrate that a concentration of 70 nM ibrutinib is sufficient to 
block Btk at its autophosphorylation site and on PLC 2 on Y753, Y759 and Y1217 
and that this effect is irreversible. At this concentration of ibrutinib, aggregation to a 
high concentration of CRP is delayed but is not blocked. At a 10-20 fold greater 
concentration, ibrutinib reversibly blocks aggregation in parallel with reversible loss 
of phosphorylation of Src on Y418. Reversible inhibition of tyrosine phosphorylation 
of other proteins is seen at a 100-fold higher concentration than that required for 
blockade of Btk. Ibrutinib causes biphasic inhibition of phosphorylation of Tec, with 
inhibition occurring at 3-5 fold higher concentrations than required to block 
phosphorylation of Btk on Y223, and full blockade at a 100 fold higher concentration. 
These results are consistent with loss of Tec autophosphorylation at 170 nM of 
ibrutinib and loss of phosphorylation on the activation site by higher concentrations. 
Low dose ibrutinib (70 nM) has no effect on platelet adhesion and aggregation 
to collagen under flow 
The relevance of the observation that aggregation is delayed but not blocked to high 
concentrations of CRP and collagen was addressed using flow studies where GPVI 
functions in conjunction with other tyrosine kinase-linked receptors that also signal 
via Btk, namely GPIb and integrin αIIbβ3. To ensure that a known degree of Btk 
blockade was achieved, washed platelets were incubated with ibrutinib at a 
concentration sufficient to fully and irreversibly inhibit Btk kinase activity (70 nM). 
Inhibition of Btk autophosphorylation was confirmed by a delay in aggregation in 
response to CRP (Figure 4A) and by measurement of phosphorylation (not shown). 
Following incubation, platelets were reconstituted with autologous red blood cells 
and platelet poor plasma and flowed over collagen at arterial shear rates. Adhesion 
of ibrutinib treated platelets was unchanged when compared to vehicle treated 
platelets (Figure 4B). 
Btk-specific concentrations of ibrutinib block GPVI mediated aggregation in 
patients with XLA 
The B cell immunodeficiency XLA is caused by mutations in the Btk gene. Using 
knowledge of patient mutations (Supplementary Table 2), and an antibody to the N-
terminus of Btk, we selected unrelated patients lacking Btk protein to test for off-
target effects of ibrutinib (Figure 5Ai). Strikingly, the concentration response curve for 
inhibition of CRP-induced aggregation by ibrutinib was shifted to the left in the XLA 
patients when compared to healthy donors (Figure 5Aii-iii), whereas the curve for 
inhibition of PLC 2 phosphorylation was unchanged (Figure 5Aiv). Since the only 
known difference between XLA patients and controls is the absence of Btk, this 
demonstrates an off-target effect of ibrutinib that is unmasked in the absence of Btk 
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protein. This off-target action occurs over a similar concentration range to that 
required for inhibition of Btk. The GPCR agonists ADP and PAR1 peptide stimulated 
robust aggregation in XLA patients, as previously demonstrated16 (not shown). 
 
One possible explanation for the increased sensitivity of XLA patients to ibrutinib 
relative to controls is that Btk also functions as an adapter protein in the GPVI 
signalling pathway (as the only known difference in these two groups is Btk protein). 
To investigate this, we transfected Btk-deficient DT40 chicken B cells with GPVI and 
its signalling partner, FcR , in the presence of wild type (WT) or kinase-dead (KD) 
Btk. Importantly, these cells express PLC 2 but do not express other Tec family 
kinases22,23. The K430E mutant of Btk has been previously reported to lack kinase 
activity24. Cells lacking Btk or GPVI were unresponsive to collagen. Cells transfected 
with WT or KD Btk reconstituted NFAT signalling to a similar degree, although there 
was a slight (Figure 6A-B) demonstrating that Btk also functions as an adapter 
protein in the GPVI signalling pathway. Low dose ibrutinib had no effect on cells 
transfected with WT or KD Btk whereas high dose ibrutinib blocked NFAT signalling 
in both WT and KD transfected cells (Figure 6C). 
 
Together these results demonstrate that Btk functions as an adapter protein, as well 
as a kinase, in XLA platelets and in transfected DT40 cells. 
 
Acalabrutinib inhibits Btk Y223 phosphorylation and platelet aggregation, 
secretion and Ca2+ mobilisation by GPVI  
Studies were extended to a second generation Btk inhibitor, acalabrutinib, which, like 
ibrutinib, irreversibly binds to Btk at C481 and is highly plasma protein bound. 
Acalabrutinib has a higher selectivity over other tyrosine kinases relative to ibrutinib, 
including Src, Syk and Tec25, but a five-fold lower IC50 for Btk17. In patients the mean 
peak free drug concentration of acalabrutinib is 1.3 μM17.  
Acalabrutinib has a similar, dose-dependent effect on platelet aggregation to that of 
ibrutinib. At a concentration of 2 μM in washed platelets, acalabrutinib induced a 
slight delay in aggregation (Supplementary Figure 3A) but had no effect on the 
overall magnitude of response (Figure 7Aii). The difference in the dose-dependency 
relative to ibrutinib is consistent with the lower IC50 of acalabrutinib for Btk. Similar to 
ibrutinib, inhibition of platelet aggregation by CRP occurs at acalabrutinib 
concentrations that are one order of magnitude higher than those which cause a 
delay in aggregation; and the curves for inhibition of ATP secretion and Ca2+ 
mobilisation lie slightly to the left of that for aggregation (Supplementary Figure 3A-
E). As with ibrutinib, acalabrutinib blocked tyrosine phosphorylation of Btk on Y223 
and PLC 2 on Y759 and Y1217 at a concentration (2 μM) that caused a delay in 
onset but no reduction in aggregation (Figure 7Ai and ii). Higher concentrations of 
acalabrutinib up to 200 μM had no effect on phosphorylation of Src Y418, Syk 
Y525/6 and LAT Y200 but caused a small reduction in phosphorylation of Btk Y551 
and SLP-76 Y145 (Figure 7Ai and 7Aiii – iv). Interestingly, acalabrutinib also caused 
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a biphasic inhibition of Tec phosphorylation with partial inhibition observed at 
approximately 1 μM and full blockade at 200 μM (Figure 7B). The IC50 values for 
each phosphorylation event are included in Supplementary Table 1. Concentrations 
of acalabrutinib that blocked phosphorylation of Btk in platelets had no effect on 
NFAT activation by CRP in DT40 cells transfected with WT or KD Btk (Figure 7C). 
Allowing for the fact that acalabrutinib has a 5-fold lower potency for Btk these 
results are in line with those for ibrutinib. 
 
GPVI-mediated platelet aggregation is blocked ex vivo in patients taking 
ibrutinib, but not acalabrutinib 
We investigated the effect of ibrutinib and acalabrutinib in patients with Chronic 
Lymphoid Leukaemia (CLL) taking ibrutinib 420 mg once daily, acalabrutinib 100 mg 
twice daily or a non-Btk targeting control chemotherapy regimen. GPVI-induced 
platelet aggregation is blocked in the PRP of patients taking ibrutinib but is not 
blocked in patients taking acalabrutinib or in the control group despite complete 
inhibition of autophosphorylation of Btk pY223 and its downstream substrate PLC 2 
at pY1217 by both inhibitors (Figure 5Bi-iv). Platelet aggregation induced by the 
GPCR agonists, ADP and PAR1 peptide, was not altered in the patients taking either 
inhibitor (not shown). 
 
Discussion 
In this study we show that (i) irreversible blockade of Btk by ibrutinib and 
acalabrutinib delays but does not block platelet aggregation by high concentrations 
of GPVI agonists; (ii) blockade of GPVI-mediated aggregation by ibrutinib and 
acalabrutinib occurs at a concentration 1-2 orders of magnitude higher than is 
required to block Btk due to an off-target action which is reversible; (iii) the ratio 
between inhibition of Btk kinase activity and platelet aggregation by GPVI is the 
same for ibrutinib and acalabrutinib; (iv) clinically relevant concentrations of ibrutinib 
but not acalabrutinib block activation of platelets by GPVI; (v) platelet adhesion and 
aggregation under flow conditions is maintained following inhibition of Btk; (vi) Btk 
supports platelet activation by GPVI by acting as an adapter protein and as a 
tyrosine kinase; and (vii) ibrutinib blocks platelet aggregation in XLA patients at 
concentrations that block Btk.  
These results show that platelets, in which Btk kinase function and downstream 
PLC 2 phosphorylation have been blocked, have a slight delay in aggregation in 
response to high concentrations of GPVI ligands, while platelet adhesion and 
aggregation under arterial flow conditions are unaltered. These observations, 
together with reports that patients with XLA or those treated with acalabrutinib do not 
experience major bleeding15,17, provide powerful evidence that inhibition of Btk does 
not give rise to major bleeding. The major bleeding observed in patients treated with 
ibrutinib relative to acalabrutinib is due to the differential dosing regimens of the two 
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Btk inhibitors, with the clinical dose of ibrutinib blocking activation of platelets by 
GPVI due to one or more off-target effects.  
The conclusion that inhibition of Btk does not give rise to major bleeding on 
treatment with ibrutinib contrasts with the conclusion of the studies by Levade et al.11 
and Bye et al.13. Levade et al.11 demonstrated a close correlation between inhibition 
of autophosphorylation of Btk at Y223 and aggregation in GPVI activated platelets. 
While we are unable to explain this in light of the present observations, we note that 
Levade et al.11 also reported that phosphorylation of PLC 2 at Y753, which is 
mediated by Btk, was inhibited at a tenfold lower concentration of ibrutinib as is seen 
in the present study. Bye et al.13 used a single, supramaximal concentration of 
ibrutinib which also blocks Src phosphorylation for their biochemical and flow based 
assays. The determination of full concentration response curves in the present study 
has highlighted the mismatch between inhibition of Btk and loss of platelet 
aggregation, and has provided evidence that the bleeding diathesis that is seen in 
some ibrutinib-treated patients is due to off-target effects.  
An unexpected observation in the present study is that platelets are able to 
aggregate to a high dose of CRP despite the absence of detectable PLC 2 
phosphorylation. One explanation for this is that Btk also supports activation of 
PLC 2 as an adapter protein as shown by the observation that transfection of 
kinase dead Btk restores GPVI signalling in DT40 cells. A similar result has been 
previously shown for Btk in B cell receptor signalling24,26. This is in keeping with 
previous studies that show that phosphorylation of PLC 2 at Y1217 is not required 
for its enzymatic activity in Ramos cells27.  
We were surprised to find that platelets from XLA patients, who lack Btk protein, 
have increased susceptibility to ibrutinib relative to platelets from controls. The only 
known difference between the XLA patients and controls in the presence of ibrutinib 
is the absence of Btk protein, although this could also change the balance of 
activatory and inhibitory phosphorylations within the GPVI signalling cascade. 
Further, the absence of Btk renders aggregation of these platelets critically 
dependent on PLC 2 phosphorylation in contrast to controls. The target for ibrutinib 
which gives rise to inhibition of aggregation in the XLA patients is not known. There 
are several kinases that are inhibited by ibrutinib over a similar concentration range 
to that for inhibition of Btk18. Within this group only Csk is known to be expressed in 
platelets28.  
We have shown that blockade of GPVI-mediated platelet aggregation by ibrutinib is 
reversible, which contrasts with the irreversible blockade of Btk and Tec18. The 
reversibility provides evidence that blockade is not mediated by inhibition of Tec 
family kinase as has been previously postulated9,11,17 as Tec also has a cysteine 
residue in its ATP binding domain analogous to C481 on Btk. This is further 
supported by the observation that ibrutinib mediated blockade of NFAT signalling in 
DT40 cells, which lack Tec, follows a similar pattern as that for platelet aggregation; 
namely no effect at low doses with blockade at high doses. For ibrutinib, we have 
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shown that inhibition of aggregation correlates strongly with loss of phosphorylation 
at Src Y418. However, this is not altered by acalabrutinib demonstrating an as yet 
unidentified off-target action. Bye et al13 also show that ibrutinib dose dependently 
inhibits phosphorylation of Src Y418. However, in a different study they report that 
both low dose ibrutinib and acalabrutinib potentiate Src Y418 phosphorylation29. We 
were not able to replicate this latter finding. 
We have shown that, despite acalabrutinib’s more favourable selectivity to Btk over 
other Src, Syk and Tec kinases in in vitro kinase assays, the window between Btk 
inhibition and blockade of GPVI-induced aggregation in vitro is similar to that of 
ibrutinib. Despite this, acalabrutinib, but not ibrutinib, fails to block GPVI-mediated 
platelet activation ex vivo. We propose that this is because of the differential dosing 
and pharmacodynamics of the two Btk inhibitors. Acalabrutinib is used at a dose of 
1.5 mg/kg twice daily17,30 and ibrutinib at a single daily dose of 6 mg/kg in CLL or 8 
mg/kg in Mantle Cell Lymphoma (MCL). Pharmacokinetic studies have shown that 
ibrutinib achieves Btk occupancy of >95% at doses of 2.5 mg/kg but that doses of 6 
mg/kg are required to maintain this over 24 hours31. Acalabrutinib at 1.5 mg/kg twice 
daily also achieves full Btk occupancy over 24 hours17. The peak unbound plasma 
concentration of ibrutinib in patients is 0.5 μM11 and that of acalabrutinib 1.3 μM17. 
The initial and terminal half-lives of ibrutinib are 2-3 hours and 4-8 hours 
respectively31. The half-life of acalabrutinib is 1 hour17. Despite the peak 
concentration of acalabrutinib being approximately 2-fold higher than the 
concentration of ibrutinib, the 5-fold lower potency of acalabrutinib as an inhibitor of 
Btk30 means that, in potency terms, it is dosed at a lower level consistent with the 
lack of inhibition of GPVI. This implies that ibrutinib could be used at a lower 
concentration to achieve Btk blockade. Indeed, there is retrospective clinical 
evidence that doses less than 6 mg/kg are as effective as 6 mg/kg at treating CLL32 
and a prospective clinical trial using doses as low as 2.5 mg/kg is being 
undertaken33.  
It is important to consider the incidence of minor and major bleeding in patients 
taking ibrutinib for CLL or at the higher dose for MCL. In reported studies involving 
patients treated with ibrutinib for MCL, minor and major bleeding is seen in 9-15% 
and 1-5% of patients respectively34,35,36. The study with the largest cohort of MCL 
patients reports a major haemorrhage rate of 5%. This is comparable to the 4-8% 
major haemorrhage rate seen in patients taking ibrutinib for CLL9. Thus, there is no 
increase in bleeding rates with higher doses of ibrutinib. This implies that the 
inhibitory effect of 420mg ibrutinib on platelets is at a physiologic maximum. 
 
During the writing of this manuscript, Bye et al. reported thrombus instability on 
collagen in a flow adhesion assay in blood treated in vitro with high doses of ibrutinib 
and ex vivo in patients treated with ibrutinib29. This is consistent with our findings that 
Btk kinase function is not required for platelet adhesion to collagen under flow, but 
that off target effects of ibrutinib seen with higher doses mediate this inhibition. They 
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also report complete blockade of platelet aggregation to supramaximal 
concentrations of collagen in patients receiving ibrutinib or acalabrutinib29 in contrast 
to the findings of this study. Bye et al. used the Optimul 96 well microtitre assay to 
measure aggregation rather than the widely used light transmission aggregometry 
(LTA). We have shown that Optimul is a more sensitive assay than LTA37,38. We 
suggest that the delay in onset of aggregation observed using LTA by concentrations 
of ibrutinib or acalabrutinib that just block Btk manifest as complete blockade in the 
Optimul assay. Bye et al. also conclude that the increased bleeding observed with 
ibrutinib is due to blockade of Src family kinases (SFK)29. We agree that bleeding 
caused by ibrutinib is due to off-target actions, and that acalabrutinib has a greater 
selectively to Btk over SFK relative to ibrutinib. However, our results show that a 
similar fold increase in the concentration of ibrutinib and acalabrutinib causes 
inhibition of platelet aggregation to CRP but without concomitant SFK blockade in 
the acalabrutinib treated platelets. Thus, the off-target action of ibrutinib and 
acalabrutinib that inhibits aggregation cannot be explained solely by differential 
blockade of SFKs. 
The results of our study explain the lack of major bleeding side effects experienced 
by patients taking acalabrutinib relative to ibrutinib and suggest that the bleeding 
side effect of ibrutinib can potentially be abolished by reducing the dose. Further, this 
study also shows that the bleeding caused by ibrutinib is not due to an irreversible 
action. This predicts that the GPVI blockade wears off over a period of 24 hours as 
the drug is cleared31. We hypothesise that, in the event of a major bleed, there may 
be no need to use expensive and potentially harmful platelet transfusions to correct 
the signalling deficit. Each clinical scenario should be judged on its own merits, 
however, and individual clinician discretion is crucial. 
In conclusion; the present study shows that inhibition of Btk kinase activity causes 
only partial inhibition of GPVI signalling in platelets and provides evidence that Btk 
supports GPVI signalling by functioning as an adapter protein as well as a kinase. 
The excessive bleeding induced by ibrutinib relative to acalabrutinib is likely to reflect 
a non-Tec family kinase off target inhibitory effect of ibrutinib, probably on Src. 
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Figure Legends 
Figure 1. Increasing ibrutinib incubation time has no effect on degree of 
inhibition of platelet aggregation and this inhibition is reversed by washing. (A) 
Representative traces of washed platelets at 4x108/ml stimulated with CRP (10 
μg/mL for 180 sec). Prior to addition of agonist, platelets were pre-incubated with 
either ibrutinib or vehicle (DMSO) for 5 min. Alongside, washed platelets at 4x108/ml 
identically treated with either ibrutinib or vehicle were washed twice in Tyrode’s buffer 
and platelets resuspended to 4x108/mL; platelets were then stimulated with CRP (10 
μg/mL for 180 sec). Data shown is representative of three identical experiments. (B) 
Mean data for (A) (n=3) analysed with one-way ANOVA. Results are shown as mean 
± SEM. * p < 0.05. (C) Washed platelets (4x108/mL) were incubated with ibrutinib or 
vehicle (DMSO) for 30 sec - 60 min before being stimulated with CRP (10 μg/mL). 
The optical density (OD) of platelet suspensions was measured in a ChronoLog 
Model 700 aggregometer with stirring at 1200 rpm. Traces representative of three 
similar experiments are shown. (D) Delay in aggregation seen with ibrutinib treated 
washed platelets (n=3) analysed with one-way ANOVA. Results are shown as mean 
± SEM. * p < 0.05.  
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Figure 2. Ibrutinib dose dependently inhibits GPVI-mediated platelet 
aggregation, ATP secretion and Ca2+ mobilisation. (A) (i) Representative traces 
showing effect of increasing doses of in vitro ibrutinib incubated for 5 min in washed 
platelets at 4x108/ml.  (ii) Ibrutinib dose response curves in washed platelets (n=7). 
(B) Representative traces showing effect of increasing doses if in vitro ibrutinib 
incubated in washed platelets at 4x108/ml for 5 min on (i) ATP secretion and (ii) Ca2+ 
mobilisation in response to stimulation with CRP (10 μg/mL) for 180 sec. (iii) Ibrutinib 
dose response curves in washed platelets of ATP secretion (n=3) and Ca2+ 
mobilisation (n=3). The dose response curve for inhibition of washed platelet 
aggregation from (Aiii) is shown as a dotted line to enable comparison. Results are 
shown as mean ± SEM. All experiments were stimulated with CRP (10 μg/mL). For 
comparison of IC50: ns = non-significant.  
 
Figure 3. Ibrutinib dose-dependently inhibits GPVI-mediated signalling. (A) 
Eptifibatide (9 μM) treated washed human platelets (4×108/mL) were stimulated with 
CRP (10 μg/mL for 180 sec) followed by lysis with 5X SDS reducing sample buffer. 
Prior to addition of agonist, platelets were pre-incubated with either ibrutinib or 
vehicle (DMSO). Some platelets underwent two further washs step prior to addition 
of agonist. (i) Whole cell lysates were then separated by SDS-PAGE and Western 
blot with the stated antibodies for whole cell phosphorylation, kinases and proteins 
downstream of GPVI. Blots are representative of three experiments. (ii) Percentage 
tyrosine phosphorylation as compared to non-washed vehicle platelets was 
measured and is represented as the means ± SEM of three identical experiments. 
(Bi) Washed platelets were treated as in (A) but with a wider range of ibrutinib doses. 
(ii - iv) The percentage of tyrosine phosphorylation as compared to vehicle treated 
platelets was measured and is represented as the means ± SEM of four identical 
experiments. The dose response curve for inhibition of washed platelet aggregation 
from Figure 2Aii is shown as a dotted line to enable comparison. (C) Eptifibatide (9 
μM) treated washed human platelets (8×108/mL) were stimulated with CRP (10 
μg/mL for 180 sec) followed by lysis with 2X ice cold lysis sample buffer. Lysates 
were pre-cleared and Tec was immunoprecipitated before addition of SDS reducing 
sample buffer and separation by SDS-PAGE and Western blot with the anti-pY 
antibody 4G10. Membranes were stripped and then reprobed with the pan-Tec 
antibody. (i) Trace is representative of three identical experiments. (ii) The 
percentage of tyrosine phosphorylation as compared to vehicle treated platelets was 
measured and is represented as the means ± SEM of three identical experiments. * 
p < 0.05. ns = non-significant. 
 
Figure 4. Low dose ibrutinib has no effect on platelet adhesion to collagen 
under flow. (A) Washed platelets (10x108/mL) we incubated with ibrutinib or vehicle 
(DMSO) for 5 min and stimulated with CRP (10 μg/mL). Representative trace (i) and 
mean data from three identical experiments (ii) show characteristic delay associated 
with inhibition of Btk autophosphorylation. (B) Platelets were reconstituted with 
autologous RBCs and PPP and flowed at arterial shear over collagen coated 
microcapillaries. (i) Representative Differential Interference Contrast (DIC) images 
are shown. (ii) Platelet coverage as percentage of vehicle treated platelets was 
calculated and is shown as mean ± SEM from three identical experiments. * p < 
0.05, ns = non significant. 
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Figure 5. XLA patients who lack Btk expression are more sensitive than 
healthy donors to ibrutinib inhibition of GPVI-mediated platelet aggregation. 
Ibrutinib, but not acalabrutinib, blocks GPVI-mediated platelets aggregation ex 
vivo. (A) Citrated blood was taken from XLA patients. (i) Whole cell lysates were 
then separated by SDS-PAGE and Western blot with the polyclonal N-terminal Btk 
antibody. PRP from XLA patients was stimulated with CRP (10 μg/mL) for 180 sec. 
(ii) Representative aggregation trace of XLA patients or healthy donor (HD). (iii) 
Ibrutinib dose response curves in washed platelets of XLA patients (n=4). Healthy 
donor responses from Figure 2Aiii are shown as a dotted line for comparison. (iv) 
Whole cell lysates were then separated by SDS-PAGE and Western blot with the 
phosphospecific antibody to PLC 2 Y1217 (n=3). XLA patient aggregation curve 
shown as dotted line for comparison. (B) Patients taking ibrutinib 420mg once daily, 
acalabrutinib 100mg twice daily or a control chemotherapy regime of Fludarabine 
(25mg/m2 IV days 1-3), Cyclophosphamide (250mg/m2 IV days 1-3) and Rituximab 
(375mg/m2 IV day 1) (FCR) had citrated blood taken on day 28 of treatment cycle (2-
3 hours post dose of Btk inhibitor). PRP from this blood was then stimulated with 
CRP (10 μg/mL) for 180 sec. (i) Representative trace. (ii) Mean and SEM from five, 
nine and three patients for FCR, ibrutinib and acalabrutinib respectively. (iii) 
Comparison of platelet counts in PRP from all patient groups. Statistical analysis was 
performed using a one way ANOVA with Tukey’s multiple comparisons test, *p < 
0.05, ns = not significant. (iv) Representative western blot from eptifibatide (9 μM) 
treated washed platelets (4×108/mL) from the same patients stimulated with CRP (10 
μg/mL for 180 sec) followed by lysis with 5X SDS sample buffer and probed with Btk 
pY223 and PLC 2 pY1217 phosphospecific antibody.  
 
 
Figure 6. Kinase dead Btk is sufficient for GPVI signalling. Btk deficient DT40 
cells were transfected with either wild type (WT) or kinase dead (KD) Btk with or 
without GPVI/FcR . All cells were transfected with a NFAT-luciferase reporter 
plasmid. Cells were stimulated with collagen (10 μg/mL) in the presence of serum. 
(A) Luciferase activity was measured and is shown as mean ± SEM of five identical 
experiments. (B) Representative western blot showing equal Btk expression in WT 
and KD transfected cells. (C) Cells were stimulated with collagen (10 μg/mL) in the 
presence or absence of ibrutinib (0.5 μM – 10 μM). Serum was excluded during 
stimulation to avoid plasma binding of the drugs. Luciferase activity between vehicle 
and drug treated samples was measured and is shown as the mean ± SEM of three 
independent experiments. * p < 0.05, ** p < 0.01.  
 
 
Figure 7. Acalabrutinib dose-dependently inhibits GPVI-mediated signalling. 
(A) Eptifibatide (9 μM) treated washed human platelets (4×108/mL) were stimulated 
with CRP (10 μg/mL for 180 sec) followed by lysis with 5X SDS reducing sample 
buffer. Prior to addition of agonist, platelets were pre-incubated with either 
acalabrutinib or vehicle (DMSO). (i) Whole cell lysates were then separated by SDS-
PAGE and Western blot with the stated antibodies for whole cell phosphorylation, 
kinases and proteins downstream of GPVI. Blots are representative of three 
experiments. (ii - iv) The percentage of tyrosine phosphorylation as compared to 
vehicle treated platelets was measured and is represented as the means ± SEM of 
three identical experiments. The dose response curve for inhibition of aggregation 
from Supplementary Figure 3D is shown as a dotted line to enable comparison. (B) 
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Eptifibatide (9 μM) treated washed human platelets (8×108/mL) were stimulated with 
CRP (10 μg/mL for 180 sec) followed by lysis with 2X ice cold lysis sample buffer. 
Lysates were precleared and Tec was immunoprecipitated before addition of SDS 
reducing sample buffer and separation by SDS-PAGE and Western blot with the anti-
pY antibody 4G10. Membranes were stripped and reprobed with the pan-Tec 
antibody. Trace is representative of three identical experiments. (C) Btk deficient 
DT40 cells were transfected with either wild type (WT) or kinase dead (KD) Btk with 
or without GPVI/FcR . All cells were transfected with a NFAT-luciferase reporter 
plasmid. Cells were stimulated with collagen (10 μg/mL) in the presence or absence 
of acalabrutinib (0.5-10 μM). Serum was excluded during stimulation to avoid plasma 
binding of the drugs. Luciferase activity between vehicle and drug treated samples 
was measured and is shown as the mean ± SEM of three independent experiments. 
ns = non-significant.  
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Supplementary Data 
Methods 
Reagents 
The α-phosphotyrosine (4G10) monoclonal antibody (mAb) was from Millipore 
(Abingdon, UK). The α-Syk pAb (SC-1077) was from Santa Cruz Biotechnology 
(Dallas, USA). The α-Btk pAb (SAB3500372) was from Sigma-Aldrich (Poole, UK). 
Phosphospecific pAbs against Syk pY525/6, PLCɣ2 pY759 and pY1217, were from 
Cell Signalling Technology (Hitchin, UK) and against LAT pY200, SLP-76 PY145, 
PLCɣ2 Y753, Btk pY223 and pY551 were from Abcam (Cambridge, UK). Ibrutinib 
(PCI-32765) and acalabrutinib (ACP-196) were from Selleckchem (Munich, Germany). 
Eptifibatide was from GSK (Brentford, UK). The α-Tec and α-Btk pAbs (BL17 and BL19 
respectively) have been described22. HRP-conjugated secondary pAbs and Hyperfilm 
ECL autoradiography film were from Amersham Biosciences (GE Healthcare, Bucks, 
UK). ECL reagent and the Ca2+ sensitive report precursor dye Fura-2-AM were from 
ThermoFisher (Waltham, MA). CRP was from Richard Farndale (Cambridge, UK). 
Collagen was made from equine tendon and sourced from Takeda (Linz, Austria). 
ChronoLume® and ATP standard were from ChronoLog Corporation (Havertown, PA). 
All other reagents were purchased from Sigma-Aldrich (Poole, UK).  
Chemical analysis of inhibitors 
Purity assessment of individual batches of ibrutinib and acalabrutinib was performed 
by High Performance Liquid Chromatography and Liquid Chromatograpy Mass 
Spectrometry. Individual batches of inhibitor were compared to each other using 
lumiaggregometry to CRP in washed platelets as a bioassay. Concentration 
calculations for each batch of inhibitor were adjusted to reflect their differences in 
potency in this bioassay when compared to the measured chemical concentration.  
 
Platelet rich plasma (PRP) and washed platelet preparation 
Blood was taken from consenting patients or healthy, drug-free volunteers, into 4% 
sodium citrate. Blood from patients, who were not taking concomitant antiplatelet 
medication, was taken at 2-3 hours after the ingestion of Btk inhibitor on the final day 
of a treatment cycle. PRP was obtained by centrifugation at 200 g for 20 min at room 
temperature. Washed platelets were obtained by centrifugation at 1,000 g for 10 min 
using 0.2 μg/mL prostacyclin and resuspended in modified-Tyrode’s-HEPES buffer 
(134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 
mM glucose, 1 mM MgCl2; pH 7.3) as previously described39. Platelets were used at 
4×108/mL for aggregation and biochemistry unless otherwise stated.  
 
Granule Release 
During LTA, 5 μL ChronoLume® (a commercial reagent containing a D-luciferin-
luciferase mixture) was added 1 min prior to insertion of glass vials into the 
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measurement chamber of the aggregometer. Light production by luciferase was 
measured by the Model 700 aggregometer. Calibration was performed by adding 5 μL 
of 2 μM ATP standard at the end of the experiment. Results were averaged and IC50 
values were calculated from these data. 
 
Measurement of [Ca2+]i 
Platelets were loaded with the Ca2+ sensitive dye Fura-2 by incubation of PRP with 2 
μM Fura-2-AM for 1 hour at 30°C. Platelets were then washed by centrifugation at 350 
g for 20 min and resuspended in modified-Tyrode-HEPES buffer. Fura-2-loaded 
platelets were incubated with inhibitors or vehicle (DMSO) for 5 min at 37°C prior to 
addition of agonists. Fluorescence measurements with excitation at 340 and 380 nm 
and emission at 510 nm were recorded over a period of 5 min using a NOVOstar plate 
reader (BMG Labtech) for experiments with ibrutinib or a FlexStation (Molecular 
Devices) for experiments with acalabrutinib. [Ca2+]i was calculated using the ratio of 
the 340 and 380 nm excitation signals according to the method of Grynkiewicz et al40. 
Results were averaged and IC50 values were calculated from these data. 
Measurement of platelet adhesion under flow 
Washed platelets were incubated with inhibitor or vehicle for 5 min. Platelets were 
added back to non-ACD treated red blood cells and Platelet Poor Plasma (PPP) to a 
final concentration of 4x108/mL. Platelets were incubated with 4 μM DiOC6 for 5 min 
to aid visualisation. Flow adhesion using a Cellix microfluidic system was performed 
as described13. Microcapillaries were subsequently fixed with 10% neutral buffered 
Formalin solution and platelet adhesion was viewed using a Zeiss Axio Observer 7 
microscope at 20X objective using fluorescence intensity emitted at 520 nm. Platelet 
surface coverage on flow adhesion microcapillary images were measured using 
ImageJ 1.5. 
Cells and plasmids 
The DT40 chicken lymphoma cell line rendered deficient in Btk41 was cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum, 1% chicken serum, 100 
U/ml penicillin, 100 μg/mL streptomycin, 20 mM glutamine and 50 μM 2β-
mercaptoethanol. GPVI, FcRɣ and NFAT-luciferase plasmids have been described 
previously42. The WT and K430E Btk plasmids have been previously described26. 
Transfections and luciferase assay 
Cells were transfected in a volume of 0.4 mL of serum free RPMI using a Gene Pulser 
II Electroporator (Bio-Rad) set at 350 V and 500 μF. Cells were transfected with 2 µg 
of both GPVI and FcRɣ, and 7.5 μg of NFAT-luciferase plasmids and where stated, 
either 5 µg WT or KD Btk plasmids. Twenty hours after transfection, live cells were 
counted by Trypan blue exclusion and diluted to 2x106/mL. Cells (50 μL) were 
stimulated with 50 μL Horm collagen (10 μg/mL final concentration) (Nycomed, 
Germany) for 6 hours. In experiments involving ibrutinib and acalabrutinib, cells were 
 3 
stimulated with collagen (10 µg/mL final) in the presence of ibrutinib (0.5-10 µM), 
acalabrutinib (0.5-10 µM) or vehicle (0.2% DMSO) for 6 hours in the absence of serum 
as these drugs have a high degree of plasma binding{Honigberg:2010hh}. Cells were 
then lysed with 11 μL of lysis buffer (10% Triton X-100, 200 mM NaPO4 (pH 7.8), and 
4 mM dithiothreitol) and added to an equal volume of assay buffer (200 mM NaPO4, 
20 mM MgCl2 and 10 mM ATP). Luciferase activity was measured using a NOVOstar 
plate reader (BMGLabtech) following the addition of 50 μL of 1 mM D-luciferin. 
Luciferase assay values were recorded in triplicate and averaged. The luciferase 
assay data were normalized to basal wild-type Btk values. 
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Supplementary Table 1. IC50 values for dose response curves (all numbers in 
μM) 
 
Ibrutinib containing figures Name of Curve IC50 
(μM) 
95% C.I. 
2Aiii HD Aggregation 1.19 0.73 – 1.95 
2B HD Secretion 0.25 0.121 – 0.548 
2B HD Ca2+ Mobilisation 1.88 0.445 – 22.18 
3Aii HD Btk pY223 0.023 0.014 – 0.036 
3Aii HD PLCɣ2 pY1217 0.035 0.019 – 0.065 
3Aii HD PLCɣ2 pY759 0.048 0.026 – 0.088 
3Aii HD PLCɣ2 pY753 0.055 0.029 – 0.105 
3Aiii HD Syk pY525/6 - - 
3Aiii HD LAT pY200 - - 
3Aiii HD SLP-76 pY145 - - 
3Aiii HD Btk pY551 - - 
3Aiv HD Src pY418 2.1 1.24 – 3.7 
5Aiii XLA Aggregation 0.086 0.037 – 0.212 
5Aiv XLA PLCɣ2 pY1217 0.035 0.014 – 0.087 
Acalabrutinib containing figures 
7Aii HD Btk pY223 0.308 0.177 – 0.549 
7Aii HD PLCɣ2 pY1217 0.88 0.393 – 2.07 
7Aii HD PLCɣ2 pY759 1.211 0.479 – 3.244 
7Aii HD PLCɣ2 pY753 2.75 1.20 – 6.59 
7Aiii HD Syk pY525/6 - - 
7Aiii HD LAT pY200 - - 
7Aiii HD SLP-76 pY145 - - 
7Aiii HD Btk pY551 - - 
7Aiv HD Src pY418 - - 
Supp Fig 3D HD Aggregation 21.25 12.27 – 37.11 
Supp Fig 3E HD Secretion 6.37 3.706 – 11.02 
Supp Fig 3E HD Ca2+ Mobilisation 5.317 2.843 – 10.15 
 
 
Supplementary Table 2. Btk mutations of XLA patients 
Patient Mutation Predicted effect 
1 c. 1750+1G>A 5’ donor site of exon 17 abolished 
2 c. 700C>T Stop codon at Gln234 
3 c. 710del Frameshift with premature termination 
4 c. 1820C>A Mutation likely to affect the kinase domain 
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Figure Legends 
 
 
Supplementary Figure 1. Ibrutinib dose dependently inhibits GPVI-mediated 
aggregation, ATP secretion and Ca2+. 
(A) Healthy donor washed platelets (4x108/mL) we incubated with ibrutinib or vehicle 
(DMSO) at the stated doses for 5 min. These were then stimulated with CRP (10 
μg/mL) or collagen (10 μg/mL) for 180 sec. (B) Washed platelets in the presence or 
absence of 0.3% BSA were incubated with ibrutinib or vehicle (DMSO) at the stated 
doses in the for the stated time before being stimulated with CRP (10 μg/mL). 
Results shown are representative of three independent experiments. * p < 0.05, ns = 
not significant. (C) Healthy donor washed platelets (4x108/mL) we incubated with 
ibrutinib or vehicle (DMSO) at the stated doses for 5 min in the presence or absence 
of 10 μM indomethacin. These were then stimulated with CRP (10 μg/mL) for 180 
sec. Data shown are mean ± SEM of three identical experiments. 
 
Supplementary Figure 2. Reducing the concentration of the CRP or the 
presence or absence of eptifibatide does not change the dose range over 
which ibrutinib has its effects or the concentration at which it blocks tyrosine 
phosphorylation at and downstream of Btk. (A) Healthy donor washed platelets 
(4x108/mL) were incubated with ibrutinib or vehicle (DMSO) at the stated doses for 5 
min. Representative traces of stimulation with CRP at (i) 10 μg/mL, (ii) 3 μg/mL or 
(iii) 1 μg/mL for 180 sec are shown. Washed platelets (4×108/mL) were stimulated for 
180 sec with (iv) CRP (3 μg/mL) in the presence of eptifibatide (9 μM) or (B) CRP 
(10 μg/mL) in the presence or absence of eptifibatide (9 μM) followed by lysis with 
5X SDS reducing sample buffer. Prior to addition of agonist, platelets were pre-
incubated with either ibrutinib or vehicle (DMSO) for 5 min. Whole cell lysates were 
then separated by SDS-PAGE and Western blot with the stated antibodies for whole 
cell phosphorylation and kinases downstream of GPVI. (C) Whole cell lysates were 
made at the time points shown after stimulation with CRP (10 μg/ml) in the presence 
or absence of low dose (70 nM) ibrutinib incubated for 5 min. These were then 
separated by SDS-PAGE and western blot was performed with the stated antibodies. 
Representative blot (i), quantification of band intensity relative to healthy donor at 
180 sec without (ii) and with (iii) low dose ibrutinib (n=3). Aggregation traces and 
blots are representative of three similar experiments.  
 
Supplementary Figure 3. Acalabrutinib dose dependently inhibits GPVI-
mediated platelet aggregation, ATP secretion and Ca2+ mobilisation. (A) 
Representative traces showing effect of increasing doses of in vitro acalabrutinib 
incubated for 5 min in washed platelets for (A) aggregometry, (B) ATP secretion and 
(C) and Ca2+ mobilisation. (D) Acalabrutinib dose response curve for aggregation in 
washed platelets (n=3). (E) Acalabrutinib dose response curves in washed platelets 
with ATP secretion (n=3) and Ca2+ mobilisation (n=3). The dose response curve for 
inhibition of washed platelet aggregation from (D) is shown as a dotted line to enable 
comparison. Results are shown as mean ± SEM. All experiments were stimulated 
with CRP (10 μg/mL).  
 
